Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00230503 | Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B | PHASE2 | COMPLETED | 220 | — | — | Jun 1, 2004 | Dec 1, 2006 | Jun 22, 2012 | - | — |
| Name | Type | Description |
|---|---|---|
| pradefovir mesylate | DRUG | - |
| adefovir dipivoxyl | DRUG | - |
Inclusion Criteria: * Compensated chronic HBV Infection * No prior treatment with adefovir dipivoxil * No interferon or lamivudine treatment for three months prior to enrollment * HBeAg positive or negative * HBV DNA viral load greater than 500,000 copies per mL * ALT between 1.2 and 10 times ULN ...